oprymea
krka, d.d., novo mesto - pramipexole dihydrochloride monohydrate - parkinson disease - anti-parkinson drugs - oprymea is indicated for treatment of the signs and symptoms of idiopathic parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations).oprymea is indicated in adults for symptomatic treatment of moderate to severe idiopathic restless legs syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).
oprymea 0.26mg modified-release tablets
consilient health ltd - pramipexole dihydrochloride monohydrate - modified-release tablet - 260microgram
oprymea 1.57mg modified-release tablets
consilient health ltd - pramipexole dihydrochloride monohydrate - modified-release tablet - 1.57mg
oprymea 2.1mg modified-release tablets
consilient health ltd - pramipexole dihydrochloride monohydrate - modified-release tablet - 2.1mg
oprymea 0.52mg modified-release tablets
consilient health ltd - pramipexole dihydrochloride monohydrate - modified-release tablet - 520microgram
oprymea 1.05mg modified-release tablets
consilient health ltd - pramipexole dihydrochloride monohydrate - modified-release tablet - 1.05mg
oprymea 3.15mg modified-release tablets
consilient health ltd - pramipexole dihydrochloride monohydrate - modified-release tablet - 3.15mg
oprymea 2.62mg modified-release tablets
consilient health ltd - pramipexole dihydrochloride monohydrate - modified-release tablet - 2.62mg
oprymea 0.088mg tablets
consilient health ltd - pramipexole dihydrochloride monohydrate - tablet - 88microgram
oprymea 0.18mg tablets
consilient health ltd - pramipexole dihydrochloride monohydrate - tablet - 180microgram